The IPO Buzz: Lafayette Acquisition (LAFAU) of Paris Raises $100 Million
Lafayette Acquisition Corp. (LAFAU) of Paris – a SPAC whose CEO Christophe Charlier is the former chairman of Russian investment bank Renaissance Capital – raised $100 million on Thursday night, Oct. 23, 2025. Lafayette Acquisition priced its SPAC IPO in sync with the terms in the prospectus – 10 million units at $10.00 each. Each unit consists of one share of stock and one right to receive one-tenth (1/10) of a share of stock upon the consummation of an initial business combination.
Lafayette Acquisition Corp. (LAFAU) is expected to start trading on Friday, Oct. 24, 2025, on the NASDAQ.
EarlyBirdCapital was the sole book-runner.
At pricing, Lafayette Acquisition Corp. (LAFAU) became the 108th SPAC IPO to get done in 2025.
The Parisian SPAC has not chosen a target sector or geography, according to the prospectus.
“We will not be limited to target businesses in any specific industry or geographic location, but intend to focus mainly on companies in the United States and on industries in which our officers and directors have had significant experience throughout their careers, which include, among others, energy, food/agri-tech, mining and metals, telecoms, financial services/fintech, natural resources, sports and entertainment, healthcare and technology,” the prospectus said.
BANKS, GOLD & BASKETBALL
Christophe Charlier has served as the chairman and CEO of Lafayette Acquisition Corp. since May 2025, according to the prospectus.
“Mr. Charlier is an international financier with 30 years of experience in investment banking, private equity and international management,” the prospectus said. “Throughout his career, he has acted as principal or advised on a number of landmark transactions in the telecom, financial services, natural resources, energy and sports and entertainment industries across developed and emerging markets.”
He also has extensive public market and SPAC experience, the prospectus said, noting that he is an independent director of Tavia Acquisition Corp., a SPAC seeking to consummate a business combination, and La Française de l’Energie, a publicly held French clean energy production company. He also served as an independent director of Oxus Acquisition Corp., which successfully completed a business combination in February 2024.
Charlier served as chairman of the board of directors of Renaissance Capital, a Moscow-based investment bank that specializes in emerging and frontier markets, from April 2017 to March 2020.
Previously, he served as deputy CEO of Onexim Group, a private equity fund founded by Mikhail Prokhorov in Moscow from September 2008 to June 2014. In this capacity, he served on the boards of directors of several of Russia’s largest companies, some of which were listed on international exchanges, and on the boards of several mid-size companies and startups in Onexim’s portfolio.
He also acted as chairman and alternate governor of the NBA’s Nets franchise from 2010 to 2014, its last two seasons in New Jersey and first two in Barclays Center in Brooklyn. He remained as a director of the Nets and Barclays Center until Mr. Prokhorov’s sale of both to Joe Tsai in 2018 and 2019.
From February 2002 to March 2004, Charlier was director of strategic development and M&A of Norilsk Nickel, a publicly held Russian company, where, among other transactions and developments, he led its acquisition of strategic stakes in Stillwater Mining Company and Gold Fields. He also actively participated in the acquisitions that led to the creation of Polyus Gold, Russia’s largest gold company.
Charlier started his investment banking career in 1995 at JPMorgan in the M&A Group in New York.
(For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.
Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading.
The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and the rating is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy.
Source: https://www.iposcoop.com/the-ipo-buzz-lafayette-acquisition-lafau-of-paris-raises-100-million/
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.

